Rapidly evolving treatment paradigm and considerations for sequencing therapies in metastatic prostate cancer—a narrative review

The treatment landscape of metastatic prostate cancer (mPCa) has evolved considerably over the past 15 years with approvals of targeted therapies such as poly-ADP-ribose polymerase inhibitors (PARPi) in castration-resistant [metastatic castration-resistant prostate cancer (mCRPC)] setting and novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Sagaram, Smitha, Rao, Arpit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review Article on Current and Future Topics on Prostate Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350255/
https://www.ncbi.nlm.nih.gov/pubmed/34430421
http://dx.doi.org/10.21037/tau-20-1383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350255/
https://www.ncbi.nlm.nih.gov/pubmed/34430421
http://dx.doi.org/10.21037/tau-20-1383

Ejemplares similares